Literature DB >> 29209657

Hitting the snooze button: Inducing quiescence with the FLT3 inhibitor quizartinib protects hematopoietic progenitors from chemotherapy.

Samuel J Taylor1, Wallace Y Langdon1.   

Abstract

Myelosuppression is one of the most severe and limiting side effects of chemotherapy. Our recent work outlines a strategy to prevent chemotherapy-induced myelosuppression by administering a priming dose of the FMS-Like Tyrosine kinase 3 (FLT3) inhibitor quizartinib. Furthermore, by administering sequential quizartinib primed injections of fluorouracil (5-FU), we demonstrated a novel and effective strategy to eliminate disease in two mouse models of quizartinib resistant acute myeloid leukemia (AML).

Entities:  

Keywords:  FLT3; acute myeloid leukemia; chemotherapy; hematopoietic progenitors; myelosuppression; quizartinib

Year:  2017        PMID： 29209657      PMCID： PMC5706937          DOI： 10.1080/23723556.2017.1378156

Source DB:  PubMed          Journal:  Mol Cell Oncol        ISSN： 2372-3556


  7 in total

1.  Transient CDK4/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion.

Authors:  Shenghui He; Patrick J Roberts; Jessica A Sorrentino; John E Bisi; Hannah Storrie-White; Renger G Tiessen; Karenann M Makhuli; William A Wargin; Henko Tadema; Ewoud-Jan van Hoogdalem; Jay C Strum; Rajesh Malik; Norman E Sharpless
Journal:  Sci Transl Med       Date:  2017-04-26       Impact factor: 17.956

2.  Flt3 inhibitor AC220 is a potent therapy in a mouse model of myeloproliferative disease driven by enhanced wild-type Flt3 signaling.

Authors:  Samuel J Taylor; Samantha A Dagger; Christine B F Thien; Matthew E Wikstrom; Wallace Y Langdon
Journal:  Blood       Date:  2012-09-18       Impact factor: 22.113

Review 3.  Antineoplastic agents and the associated myelosuppressive effects: a review.

Authors:  Jason N Barreto; Kristen B McCullough; Lauren L Ice; Judith A Smith
Journal:  J Pharm Pract       Date:  2014-08-20

4.  An open-label, single-dose, phase 1 study of the absorption, metabolism and excretion of quizartinib, a highly selective and potent FLT3 tyrosine kinase inhibitor, in healthy male subjects, for the treatment of acute myeloid leukemia.

Authors:  Madhu Sanga; Joyce James; Joseph Marini; Guy Gammon; Christine Hale; Jianke Li
Journal:  Xenobiotica       Date:  2017-07-25       Impact factor: 1.908

5.  AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).

Authors:  Patrick P Zarrinkar; Ruwanthi N Gunawardane; Merryl D Cramer; Michael F Gardner; Daniel Brigham; Barbara Belli; Mazen W Karaman; Keith W Pratz; Gabriel Pallares; Qi Chao; Kelly G Sprankle; Hitesh K Patel; Mark Levis; Robert C Armstrong; Joyce James; Shripad S Bhagwat
Journal:  Blood       Date:  2009-08-04       Impact factor: 22.113

6.  Preventing chemotherapy-induced myelosuppression by repurposing the FLT3 inhibitor quizartinib.

Authors:  Samuel J Taylor; Johanna M Duyvestyn; Samantha A Dagger; Emma J Dishington; Catherine A Rinaldi; Oliver M Dovey; George S Vassiliou; Carolyn S Grove; Wallace Y Langdon
Journal:  Sci Transl Med       Date:  2017-08-09       Impact factor: 17.956

7.  Overcoming myelosuppression due to synthetic lethal toxicity for FLT3-targeted acute myeloid leukemia therapy.

Authors:  Alexander A Warkentin; Michael S Lopez; Elisabeth A Lasater; Kimberly Lin; Bai-Liang He; Anskar Yh Leung; Catherine C Smith; Neil P Shah; Kevan M Shokat
Journal:  Elife       Date:  2014-12-22       Impact factor: 8.140
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.